Skip to main content
. 2021 Feb 23;6(1):e00985-20. doi: 10.1128/mSystems.00985-20

FIG 3.

FIG 3

Impaired microbiota-derived AHR ligands in saccharin- and sucralose-treated mice. (A to D) Total concentrations of AHR agonists (indole, IAA, IPA, indole acrylic acid, and indole-3-aldehyde) from fecal, colonic, serum, and liver samples of the control, NHDC, saccharin, and sucralose treatment groups. (E to H) Concentrations of indole from fecal, colonic, serum, and liver samples. (I to L) Concentrations of IAA from fecal, colonic, serum, and liver samples. (M and N) Hepatic and colonic levels of Ahr mRNA. (O and P) Hepatic and colonic levels of Cyp1a1 mRNA. (Q and R) Levels of hepatic and colonic AHR protein. (S and T) Hepatic and colonic AHR activity. (U to X) Spearman correlations of serum AHR agonists, ileum Ptprh, and serum CD14, LPS, and IL-6. Data are means ± SD (n = 10 per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001.